Patients are very satisfied with Givlaari (givosiran), the only approved treatment that targets the cause of acute hepatic porphyria (AHP) to help reduce attacks, according to a new study based on interviews with more than 20 people with AHP in the U.S. and Europe. Indeed, these AHP patients —…

In a real-world study in Germany, Givlaari (givosiran) was found to effectively prevent severe acute attacks and reduce chronic health burden in people with acute intermittent porphyria (AIP) — patients who are commonly excluded from porphyria studies and who would have been ineligible to participate in the…

Note: This story was updated Oct. 25, 2024, to correct that hemin was used during this study to treat porphyria attacks. Long-term use of the approved therapy Givlaari (givosiran) safely led to sustained reductions in porphyria attacks, and in the need for medications to treat such attacks, in…

The case of a 16-year-old girl with recurrent acute intermittent porphyria (AIP) attacks who saw her symptoms ease after she started treatment with Givlaari (givosiran) has been reported in the U.S. The injectable therapy in the U.S. is approved only for adults with acute forms of porphyria, unlike…

The dosing of Givlaari (givosiran) may be personalized for people with acute intermittent porphyria (AIP), who are in stable condition after one year of treatment. That’s according to a recent study that described the cases of three women for whom treatment normalized the levels of delta-aminolevulinic acid (ALA),…

Givlaari (givosiran) safely led to a complete resolution of annual attacks in people with acute hepatic porphyria (AHP), according to real-world data from a case series study in Italy. Long-term treatment also led to sustained reductions in key markers of AHP, along with gains in physical function. A trend for…

High levels of the amino acid homocysteine — a potentially harmful side effect of Givlaari (givosiran) — were successfully normalized by vitamin B6 supplementation in a woman with hard-to-treat acute intermittent porphyria (AIP), as described in a recent case report. “Our results confirmed the importance of monitoring homocysteine…

Treatment with Givlaari (givosiran) was effective for resolving symptoms of hereditary coproporphyria (HCP) in a 47-year-old Japanese woman, according to a recent report. Her symptoms remained well-controlled for more than two years after stopping Glivlaari, according to the report, “A Case of Hereditary Coproporphyria in…

Treatment with Givlaari (givosiran) successfully resolved acute attacks of acute intermittent porphyria (AIP) in a 36-year-old woman who had been experiencing recurrent bouts of abdominal pain over the prior three years. According to researchers, this is the first report supporting the use of Givlaari “as an effective therapeutic…

Certain people with acute hepatic porphyria (AHP) living in British Columbia may now get full coverage of Givlaari (givosiran) through BC PharmaCare. BC PharmaCare is a publicly funded program in British Columbia that helps residents of the Canadian province pay for certain prescription drugs and some other…